Figure 7.

Bivalent PeptiENV Targeting gp100 and Trp2 Induces Robust Infiltration of Tumor-Specific CD8⁺ Effector T Cells into the Tumor in a Syngeneic Mouse Model of B16-F10 Melanoma

(A–C) Tumor growth curves for each mouse/group are shown. C57BL/6 mice were inoculated subcutaneously in right flank with 1 × 10⁵ B16-F10 melanoma cells, and mice were treated on days 10, 11, 12, 13, 17, and 18 with (C) gp100/Trp2-PeptiENV VACV (n = 7), (B) VACV (n = 7), or (A) injection media alone as mock (n = 5). A threshold of 450 mm³ was set to define the percentage of mice responding to the different therapies (dotted line). The percentage of responders in each treatment group is shown on the right side of the dotted line. The percentage of CD19⁻ CD8⁺ tumor-infiltrating gp100-specific CD8⁺ T cells (D) and CD19⁻ CD8⁺ tumor-infiltrating Trp2-specific CD8⁺ T cells (E) of the total number of CD19⁻ CD8⁺ cells were assessed for each group. Data shown as mean ± SEM. *p < 0.05 (one-way ANOVA). Flow cytometry was performed with three biological replicates and two technical replicates from each sample.